The BAZ1A Knockout SK-HEP-1 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population in which BAZ1A gene function is disrupted within a human hepatic adenocarcinoma background. This loss-of-function model enables investigation of the WSTF-ISWI chromatin remodeling complex (WICH) and its roles in DNA replication and chromatin dynamics. The polyclonal format retains genetic heterogeneity, suitable for robust functional genomics studies without clonal artifacts.
Derived from human hepatocellular carcinoma, the SK-HEP-1 host cell line displays an epithelial, tumorigenic phenotype and is extensively used in liver cancer research. This line models key aspects of hepatic adenocarcinoma, including oncogenic signaling and chromosomal instability, providing a relevant biological context for studying chromatin regulation and replication stress.
BAZ1A encodes a regulatory subunit of the WICH complex, which orchestrates SMARCA5-mediated chromatin remodeling at replication forks within pericentric heterochromatin. The protein interacts with PCNA and histone H3 to coordinate remodeling with replication fork progression, thereby ensuring faithful DNA synthesis through condensed genomic regions. Upstream, BAZ1A activity is governed by the cell cycle machinery and CDK signaling, linking chromatin dynamics to proliferation control. Downstream, BAZ1A promotes heterochromatin maintenance and replication fork stability; its loss disrupts these processes and compromises the DNA damage response, underscoring its essential genome caretaker function.
Within the SK-HEP-1 hepatocellular carcinoma context, BAZ1A knockout creates a model of replication stress and heterochromatin erosion pertinent to liver oncogenesis. The edited cells exhibit heightened susceptibility to replication fork stalling and DNA lesions, mirroring the genomic instability prevalent in aggressive hepatic adenocarcinomas. This system facilitates exploration of synthetic lethal interactions between WICH complex deficiency and DNA damage repair pathways, offering a platform to identify novel therapeutic targets in liver cancer. The polyclonal architecture further recapitulates tumor heterogeneity, enhancing translational relevance.
Applications span cancer biology, chromatin research, DNA replication, and DNA damage repair. Compatible assays include western blotting and RT-qPCR for expression analysis, immunofluorescence for subcellular localization, flow cytometry for cell cycle profiling, EdU incorporation to quantify replication dynamics, ChIP-qPCR to assess chromatin interactions, comet assays for DNA damage, and proliferation or drug sensitivity profiling. For further information, please contact Ascent Research.
